| 【公司研究】兴达国际 (1899 HK) – 销量和毛利共同推动盈利复苏 |
| 【行业研究】中国房地产 – 市场对贷款上限反应过度后；良好买入时机 |
| 【公司研究】天伦燃气 (1600 HK) – 新项目并购将提升2021年收益 |
| 【Fixed Income Research】Yestar – can it avert a default? (YESTHEA) |
| 【Company Research】Simcere Pharmaceutical Group (2096 HK) – Transitioning from generic to innovative |
| 【Company Research】CIMC Vehicles (Group) (1839 HK) – More catalysts in 2021E |
| 【Company Research】China Technology Sector – Global smartphone recovery to continue in 2021; Prefer share gainers and Xiaomi/Apple plays |
| 【Company Research】China Technology Sector – Time to revisit China 5G supply chain; Positive catalysts on the horizon |
| 【Company Research】InnoCare Pharma (9969 HK) – Orelabrutinib received approvals for treating r/r-CLL/SLL and r/r-MCL in China |
| 【Company Research】iHuman Inc. (IH US) – Let children learn with fun |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
